Abstract | Background: Methods: OPV has been provided in 3 contexts: (1) coadministration of OPV and diphtheria- tetanus- pertussis ( DTP) vaccine at 6, 10, and 14 weeks of age; (2) at birth (OPV0) with BCG; and (3) in OPV campaigns (C-OPVs) initiated to eradicate polio infection. We searched PubMed and Embase for studies of OPV with mortality as an outcome. We used meta-analysis to obtain the combined relative risk (RR) of mortality associated with different uses of OPV. Results: First, in natural experiments when DTP was missing, OPV-only compared with DTP + OPV was associated with 3-fold lower mortality in community studies (RR, 0.33 [95% confidence interval {CI}, .14-.75]) and a hospital study (RR, 0.29 [95% CI, .11-.77]). Conversely, when OPV was missing, DTP-only was associated with 3-fold higher mortality than DTP + OPV (RR, 3.23 [95% CI, 1.27-8.21]). Second, in a randomized controlled trial, BCG + OPV0 vs BCG + no OPV0 was associated with 32% (95% CI, 0-55%) lower infant mortality. Beneficial NSEs were stronger with early use of OPV0. Third, in 5 population-based studies from Guinea-Bissau and Bangladesh, the mortality rate was 24% (95% CI, 17%-31%) lower after C-OPVs than before C-OPVs. Conclusions: There have been few clinical polio cases reported in this century, and no confounding factors or bias would explain all these patterns. The only consistent interpretation is that OPV has beneficial NSEs, reducing nonpolio child mortality.
|
Authors | Peter Aaby, Sebastian Nielsen, Ane B Fisker, Line M Pedersen, Paul Welaga, Syed M A Hanifi, Cesario L Martins, Amabelia Rodrigues, Konstantin Chumakov, Christine S Benn |
Journal | Open forum infectious diseases
(Open Forum Infect Dis)
Vol. 9
Issue 8
Pg. ofac340
(Aug 2022)
ISSN: 2328-8957 [Print] United States |
PMID | 35937644
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |